Mairs & Power Comments on Cray

Guru stock highlight

Author's Avatar
Dec 01, 2015

Cray (CRAY, Financial) continues to gain significant share in the high performance computing space against the market leader, IBM, as that company continues to reposition itself away from the space. At the same time, Cray is starting to gain traction with commercial sales, in addition to its core government and academic customer base. Cardiovascular Systems has suffered setbacks in significantly growing and cross-training its existing salesforce, which hurt near term performance. Nevertheless, we believe its solution to peripheral arterial disease which can save a patient’s extremities from potential amputation makes a lot of sense and has a lot of room to grow. Likewise recent FDA approval of the company’s solution to dealing with calcified arteries near the heart before angioplasty or stenting also appears to serve an unmet need. Revenue growth has been lumpy as the company attempts to build out these two new markets, but over the long term we expect they will be successful

From Mairs & Power Small Cap Fund third quarter 2015 commentary.